A bump up in sales of Covid-19 related products that contributed to an 18.4% rise in community pharmacy revenue during the first half was unlikely to be matched in the rest of the 2023 financial year, said Ebos Group chief executive John Cullity.
Overall the NZX and ASX-listed healthcare and animal
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
